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Currently, peripheral blood stem cells (PBSC) mobilized by hematopoietic growth factors are largely used as a source of stem cells for alloge-
neic transplantation.1 There are differences in the evolu-
tion of disease depending on the source of transplanted 
cells. Recovery of circulating neutrophils and platelets oc-
curs earlier in the PBSC transplant.2,3 On the other hand, 
a higher incidence of chronic graft-versus-host disease 
(GVHD) is described in most trials after PBSC trans-
plant.4,5 Only one randomized clinical trial has compared 
PBSC and bone marrow (BM) transplantation in Brazil,6 
although some centers, including ours, have started to use 
PBSC for most but not all patients. The goal of this ret-
rospective study was the assessment and comparison of 
the clinical evolution of 364 patients who had undergone 
allogeneic transplantation with PBSC or BM. 
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BACKGROUND AND OBJECTIVES: disease evolution depends in part on the source of transplanted cells. 
therefore, we compared outcomes after allogeneic bone marrow (bm) and peripheral blood stem cell (pbsc) 
transplantation in patients who underwent transplant at hospital das clinicas of the federal university of minas 
Gerais, brazil. 
PATIENTS AND METHODS: We studied 364 patients who received allogeneic bm (n=142) or pbsc transplan-
tation (n=222) between July 1995 and may 2005. the median age of the patients was 31 years (range, 3.1-58 
years). chronic myeloid leukemia was the predominant diagnosis (41.2%). a conditioning regimen with cy-
closphosphamide and busulfan was used in 79.4% (n=289) and graft-versus-host disease (GVhd) prophylaxis 
was cyclosporine/methotrexate in 95.9% (n=349) of cases. 
RESULTS: the patients in the pbsc group had faster neutrophil (p<.001) and platelet engraftment (p=.03) but 
increased rates of acute GVhd (p<.001) vs. those in the bm group. there was no significant difference between 
the groups in chronic GVhd, transplant-related mortality, relapse and survival rates. 
CONCLUSIONS: although allogeneic pbsc transplant results in a faster hematopoietic engraftment, there was 
an increase in acute GVhd. there was no clear benefit in relapse rate and no evidence that transplantation with 
pbsc benefits patient survival in our institution. 
PATIENTS AND METHODS
This study was previously approved by the local eth-
ics committee. Two groups of patients who under-
went allogeneic transplantation at the Bone Marrow 
Transplantation Unit of the Clinical Hospital/ Federal 
University of Minas Gerais, Brazil, from July 1995 to 
May 2005 were studied. The first group included pa-
tients who received allogeneic bone marrow transplan-
tation (BM group; n=142) and the second, patients who 
received allogeneic peripheral blood stem cell transplan-
tation (PBSC group, n=222) after stimulating donors 
with five days of G-CSF. Only the first allogeneic bone 
marrow transplant was included in this study. There was 
a predominance of male gender (n=205, 56.3%). The 
median age of patients and donors was 31 years (range, 
3.1-58 years) and 30.4 years (range, 1.7-66 years), re-
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spectively. Sixty-five patients (17.9%) were children 
(age less than 18 years old). The median time between 
diagnosis and transplant was 1.1 years (minimum of 36 
days and maximum of 16.6 years). Leukemias predomi-
nated as indication for transplant: chronic myeloid leu-
kemia/CML (41.2%), acute myeloid leukemia/AML 
(19.5%) and, acute lymphoid leukemia/ALL (10.7%). 
Bone marrow failure syndrome (mainly severe aplastic 
anemia) was the indication for transplant in 18.1% of 
patients. Two hundred thirty-four patients presented 
with a disease classified as low risk (64.3%) and 130 
as high risk (35.7%). For statistical purposes, we con-
sidered the following as low risk: CML in first chronic 
phase, AML/ALL in first remission, myelodisplastic 
syndrome as refractory anemia with or without ringed 
sideroblasts, and non-malignant diseases. Serology for 
cytomegalovirus (CMV) in the patient/donor pair 
was positive in 82% of the cases before the transplant. 
Only related hematopoietic stem cell transplants were 
included, and 357 pairs were HLA-identical siblings 
(98.1%). A conditioning regimen using cyclophospha-
mide and busulphan was used in 79.4% of the patients; 
45 (12.4%) patients received busulphan (4 mg/kg) and 
cyclosphosphamide (200 mg/kg), while 244 (67%) pa-
tients received busulphan (16mg/kg) and cyclosphos-
phamide (120mg/kg). Acute GVHD prophylaxis em-
ployed the combination of cyclosporine and methotrex-
ate in 95.9% of the cases. The median nucleated infused 
cells were 2.8× 108 cells/kg (range, 1.2-17.3) in the BM 
group and 4.0×108cells/kg (range, 1.5-17) in the PBSC 
group. Infused CD34+ cell dose was not analyzed since 
in none of the patients that received bone marrow as 
graft source had this count been performed. Patient and 
donor characteristics are shown on Table 1.
Neutrophil recovery was defined as the first of three 
consecutive days with an absolute number of neutro-
phils >0.5×109/L. Platelet recovery was defined as the 
time to reach a sustained platelet count >20×109/L in 
the absence of platelet transfusions for seven consecu-
tive days. All patients were considered at risk starting 
on day 1 for the occurrence of acute GVHD, whereas 
only those surviving for more than 100 days after trans-
plant and who had sustained engraftment were evalu-
ated for the development of chronic GVHD. Acute 
and chronic GVHD were defined according to defined 
criteria.7,8 Transplant-related mortality (TRM) at one 
year was defined as all causes of deaths at one year after 
transplant not related to relapse. Time to relapse was 
calculated from the time between transplant and any 
evidence of relapse of the malignant disease. Overall 
survival was the time between transplantation and 
death due to any cause.
Data were analyzed as of 30 June 2008. TRM and 
overall survival were calculated by the Kaplan-Meier 
method, comparing the groups with the log-rank test. 
Neutrophil and platelet recoveries, acute and chronic 
GVHD and relapse were evaluated by a cumula-
Table 1. Patient and donor characteristics.
All patients Bone marrow Peripheral blood stem cell
364 (100%) 142 (39%) 222 (61%)
Patient male gender 205 (56.3%) 89 (62.7%) 116 (52.3%)
Patient age (years) 31.0 (3.1-58) 26.6 (3.1-54.4) 32.3 (8.6-58)
Children (<18 years old) 65 (17.9%) 37 (26.1%) 28 (12.6%)
Donor male gender 195 (53.9%) 64 (45.1%) 131 (59.5%)
Female donor to male 
recipient 91 (25.1) 46 (32.4%) 45 (20.5%)
Time from diagnosis to 
transplant (years) 1.05 (0.1-16.6) 0.81 (0.1-8.4) 1.25 (0.1-16.6)
Diagnosis
   CmL 150 (41.2%) 60 (42.3%) 90 (40.5%)
   AmL 71 (19.5%) 9 (6.3%) 62 (27.9%)
   ALL  39 (10.7%) 6 (4.3%) 33 (14.9%)
   mDS 16 (4.4%) 3 (2.1%) 13 (5.9%)
   Other malignancies 15 (4.1%) 3 (2.1%) 12 (5.4%)
   Severe aplastic anemia 66 (18.1%) 57 (40.1%) 9 (4.1%)
   Other non-    
   malignancies 7 (1.9%) 4 (2.8%) 3 (1.4%)
risk classification
   Low 234 (64.3%) 122 (85.9%) 112 (50.5%)
   High 130 (35.7%) 20 (14.1%) 110 (49.5%)
Nucleated cell infused/
kg 3.7 (1.2-17.3)×10
8 2.8 (1.2-17.3)×108 4.0 (1.5-17)×108
CmV positive serology 
(patient/donor pair) 
(n=319)
306 (95.9%) 114 (95.8%) 192 (96%)
Conditioning
   BuCy 16/120 244 (67%) 76 (53.5%) 168 (75.7%)
   BuCy 4/200 45 (12.4%) 38 (26.8%) 7 (3.1%)
   Others 75 (20.6%) 28 (19.7%) 47 (21.2%)
GVHD prophylaxis
   CSA+mTX 349 (95.9%) 140 (98.6%) 209 (94.1%)
Values are n (%) or median (range). CmL: chronic myelogenous leukemia, AmL: acute myelogenous leukemia, 
ALL: acute lymphoblastic leukemia, mDS: myelodysplastic syndrome, CmV: cytomegalovirus, BuCy: busulphan/
cyclophosphamide, CSA: cyclosporine, mTX: methotrexate.
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tive incidence curve, with death as a competing event. 
Differences between the groups were compared using 
the Fine and Gray method. All potential prognostic 
variables with a P<.10 in univariate analysis were in-
cluded in a Cox regression model (Table 2). Graft 
source (PBSC versus BM) were included in all models. 
P values of less than .05 were considered statistically 
significant. Statistical analysis was performed using the 
SPSS 11.5 and S-Plus 6.1 software.
RESULTS
The cumulative incidence of neutrophil recovery was 
91.2% in 60 days for the whole population. Compared 
to the BM group, neutrophil recovery occurred faster 
in the PBSC group (P<.001, Figure 1). Median time to 
neutrophil recovery was 15 days (range, 8-42 days) for the 
PBSC group and 22 days (range, 12-36 days) for the BM 
group. Multivariate analysis confirmed a faster neutrophil 
engraftment for PBSC graft (hazard ratio=1.98; 95% 
CI=1.55-2.52, P<.001) and for female patients (HR 
=1.39; 95% CI =1.10-1.75, P=.005). Platelet recovery 
(>20×109/L) was 83% in 100 days (cumulative inci-
dence). In a univariate analysis, there was no difference in 
the PBSC group compared to the BM group in platelet 
recovery (P=.37). The median times for platelet recov-
ery were 12 days (range, 0-74 days) and 16 days (range, 
0-60 days) for the PBSC and BM groups, respectively. 
However, in the multivariate analysis, platelet recovery 
was faster in the PBSC group (hazard ratio=1.33; 95% 
CI=1.03-1.72, P=.03). The cumulative incidences of 
acute GVHD (day +100) for the BM and PBSC groups 
were 32.4% and 58.6%, respectively (P<.001) (Figure 
2). In multivariate analysis, use of PBSC as graft source 
resulted in a higher incidence of acute GVHD (hazard 
ratio=2.4; 95% CI=1.62-3.56, P<.001). On the contrary, 
patients less than 18 years of age showed a lower incidence 
of acute GVHD (hazard ratio=0.53; 95% CI=0.33-0.87, 
P=.01). At day +100, cumulative incidences of grade 2-4 
acute GVHD for the BM and PBSC groups were 23% 
and 38%, respectively. Table 3 shows the cumulative in-
cidence of acute GVHD 2-4 by grade according to stem 
cell source. This was confirmed in multivariate analysis 
where PBSC emerged as the sole variable associated with 
a higher incidence of grade 2-4 acute GVHD (hazard ra-
tio=1.92; 95% CI=1.28-2.87, P=.002). 
The cumulative incidences of chronic GVHD at 6 
years for the BM and PBSC groups were 47% and 68%, 
respectively (P<.001). Twenty-seven patients from the 
BM group and 78 from the PBSC group developed 
extensive chronic GVHD. In a multivariate analy-
sis there was no difference in the incidence of chronic 
GVHD between the BM and PBSC groups (hazard 
ratio=1.37; 95% CI=0.95-1.97, P=.09). A female do-
nor to a male recipient was associated with a higher 
incidence of chronic GVHD (hazard ratio=1.82; 95% 
CI=1.25-2.66, P=.002). On the other hand, protec-
tion from chronic GVHD was observed in patients less 
than 18 years of age (hazard ratio=0.54; 95% CI=0.32-
0.91, P=.02) and in severe aplastic anemia patients 
(HR=0.33; 95% CI=0.12-0.89, P=.03). 
One hundred twenty-four deaths were related to 
transplant. The main cause of death was GVHD. The 
cumulative incidence TRM at one year was 34.7%, in-
cluding 25.1% and 40.8% for the BM and PBSC groups, 
respectively. Although univariate analysis (P=.001) 
showed a higher probability of TRM for the PBSC 
group at one year, multivariate analysis (hazard ra-
tio=1.45; 95% CI=0.93-2.26, P=.10) did not confirm 
this finding. High-risk disease correlated with a higher 
risk of TRM (hazard ratio=1.56; 95% CI=1.06-2.30, 
P=.02). Patients less than 18 years old presented with 
Table 2. Variables included in Cox regression models.
Outcomes Variables included (if P<.10 in univariate analysis)
Neutrophil recovery Source, gender, female donor to male recipient, CmV serology 
Platelet recovery Source, gender, risk classification
Acute graft-versus-host 
disease
Source, risk classification, children, malignancy, 
severe aplastic anemia
Acute graft-versus-host 
disease grade 2-4 Source, children, malignancy, CmV serology
Chronic graft-versus-host 
disease
Source, female donor to male recipient, children, 
malignancy, severe aplastic anemia
Transplant-related mortality Source, risk classification, children, malignancy 
relapse Source, risk classification, children 
Overall survival Source, risk classification, malignancy, severe aplastic anemia, children
Table 3. Cumulative incidence of acute GVHD 2-4 by grade according to stem cell 
source.
Acute GVHD
grade
Source
Total
Bone marrow Peripheral blood stem cell
0 - 1 109 (76.8%) 138 (62.2%) 247 (67.9%)
2 16 (11.3%) 24 (10.8%) 40 (11,0%)
3 4 (2.8%) 35 (15.8%) 39 (10.7%)
4 13 (9.2%) 25 (11.3%) 38 (10.4%)
Total 142 (100%) 222 (100%) 364 (100.0%)
Values are n (%).
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a lower TRM rate (hazard ratio=0.28; 95% CI=0.13-
0.58, P=.001).
The incidences of relapse in 6 years for malignancy 
diseases were 23.7% and 21.8% for the BM and PBSC 
groups, respectively. Both univariate (P=.88) and mul-
tivariate analysis (hazard ratio=0.75; 95% CI=0.42-
1.35, P=.34) showed no difference in relapse between 
the two groups. High-risk disease correlated, as ex-
pected, with a higher probability for relapse (hazard 
ratio=5.68; 95% CI=3.13-10.32, P<.0001). 
At the end of follow-up, 171 patients were alive 
(47%). The probability of overall survival at 6 years for 
the BM and PBSC groups were 63.6% and 38.1%, re-
spectively. Univariate analysis showed that the PBSC 
group had a lower overall survival than the BM group 
(P<.0001). In multivariate analysis, no difference was 
observed (hazard ratio=1.29; 95% CI=0.89-1.86, 
P=.17). There was a correlation between high-risk dis-
ease (hazard ratio=2.75; 95% CI=1.99-3.81, P<.0001) 
and a decrease in overall survival. Age below 18 years 
was associated with a better overall survival (hazard ra-
tio=0.66; 95% CI=0.44-0.99, P=.05).
DISCUSSION
The success of hematopoietic stem cell transplantation 
in the complete reconstitution of bone marrow function 
is related to the cellular elements of marrow recovery 
and to the functional recovery of the immune cells. 
While the former occurs after a few weeks, the second 
occurs gradually. Sometimes more than one year is re-
quired for a patient to develop a complete cellular and 
humoral immunity.9,10 Transplantation using PBSC is 
associated with faster blood cell and immunity recover-
ies.6,11-14 However, despite having these advantages, sev-
eral studies concluded that PBSC use is not associated 
with a better overall survival.2,4-6,15,16 The present study 
aimed to determine whether clinical trial results are re-
flected in daily clinical practice.
In our study, hematological recovery was faster in the 
PBSC group than in the BM group. The median neutro-
phil recovery was 7 days less in the PBSC group than in 
the BM group. Platelet recovery was also shorter in the 
PBSC group. These results are in accordance with the 
literature.2,3, 6,12,15-18 The use of G-CSF to mobilize hema-
topoietic stem cells in autologous and allogeneic PBSC 
transplants increases CD34+ cells in the graft and ac-
celerates hematopoietic recovery.18-20 Unfortunately, the 
impact of this variable cannot be analyzed because of the 
absence of this information in the hospital records of al-
most all transplanted BM patients.
In this study, a significant increase in acute GVHD 
incidence and severity was observed in the PBSC 
group. The incidence of moderate-severe (grade 2-4) 
and severe (grade 3-4) acute GVHD were significant-
ly higher in the PBSC group. In agreement with this 
finding, two previous studies and a meta-analysis also 
reported an increase in acute GVHD incidence in pa-
tients who received PBSC.5,21,22 However, most of the 
clinical studies found no difference in the occurrence 
of acute GVHD.2,5,6,12,15,18 An increase in the cumula-
tive incidence of chronic GVHD in the PBSC group 
was observed, but it did not achieve statistical signifi-
cance. Most studies showed an increase on the inci-
dence of chronic GVHD.2,3, 21-24 The fact that a PBSC 
graft has roughly one log of T lymphocytes more than 
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Figure 1. Cumulative incidence of neutrophil recovery for the bone marrow (Bm) and 
peripheral blood stem cell (PBSC) groups at D+60.
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Figure 2. Cumulative incidence of acute graft versus host disease for the bone marrow 
(Bm) and peripheral blood stem cell (PBSC) groups at D+100.
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a BM graft20 and G-CSF, used in PBSC mobilization, 
polarizes Th lymphocytes to a Th2 phenotype,25,26 justi-
fies the higher chronic GVHD incidence in allogeneic 
PBSC transplants. In the present study, a higher chron-
ic GVHD incidence was observed when a female donor 
donated to a male recipient and in older patients. It is 
well known that these two factors constitute a chronic 
GVHD risk.27 A selection bias might explain the in-
crease in acute GVHD and the tendency for a higher 
chronic GHVD rate in the PBSC group in our study. 
As graft selection was not determined by chance, the 
two groups were not well balanced. There was a pre-
dominance of aplastic anemia in the BM group, a diag-
nosis usually associated with less GVDH.28 
Although a lower incidence of relapse was observed 
in the PBSC group in our study, the difference was not 
significant, which is consistent with some studies.4,12 
However, a meta-analysis of nine clinical trials report-
ed a significantly lower relapse incidence in the PBSC 
group than in the BM group.5 It is known that chronic 
GVHD is associated with a lower relapse incidence.29,30 
Thus, a lower relapse incidence was expected in PBSC 
group, but this result was not observed. A probable 
reason for this result was a bias to a more frequent use 
of PBSC in patients with a higher-risk features (more 
advanced phase of disease, more chemotherapy treat-
ment and a poorer performance status at the time of 
transplant) and, in consequence, they died early after 
transplant without enough time to relapse. 
TRM showed a tendency to be higher in the PBSC 
group in our study. Not surprisingly the main cause of 
death related to transplants in this study was GVHD. 
This finding agrees with other studies that showed 
GVHD to be the one of the most frequent complica-
tions after allogeneic bone marrow transplants.31,32 
The trend for an increase in TRM in the PBSC group 
might also be due to a higher number of high-risk ma-
lignancies in this group, a known prognostic factor for 
TRM.33,34 Some authors argue that short-term TRM 
among patients who receive PBSC could be reduced by 
a faster hematological recovery.3,12 Most of the studies, 
however, have shown no difference in short-term TRM 
between PBSC and BM groups.4,5,35 
Even if the univariate analysis had shown that overall 
survival was higher in BM group, this was not confirmed 
in the multivariate analysis. Some studies have shown 
an improvement in the overall survival of patients with 
advanced diseases who received PBSC.4,5 This trend 
for a higher overall and disease-free survival in the BM 
group is probably related to a lower number of patients 
with high-risk features in this group. It seems that the 
effect of PBSC on survival was eclipsed by the far high-
er frequency of high-risk patients in PBSC group, as 
showed in the multivariate analysis. 
In conclusion, this study showed that certain advan-
tages of PBSC, such as faster hematological recovery 
were, unfortunately, counterbalanced by an increase in 
acute GVHD incidence. The retrospective character of 
this study, as well as the heterogeneity of the diseases 
does not allow definitive conclusions with respect to the 
advantages and disadvantages for survival in relation to 
the source of stem cells. Although some studies have 
questioned the use of PBSC in low-risk diseases0 and 
children,36 an increase in transplants using PBSC has 
been observed worldwide. In our institution, the choice 
of this source was re-evaluated in some situations. Use 
of BM, especially in a low-risk of relapse situation has 
been reconsidered and is now our first option.
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